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Abstract
Some have suggested that chronic obstructive pulmonary disease (COPD) is a disease of accelerated aging. Aging is
characterized by shortening of telomeres. The relationship of telomere length to important clinical outcomes such as
mortality, disease progression and cancer in COPD is unknown. Using quantitative polymerase chain reaction (qPCR), we
measured telomere length of peripheral leukocytes in 4,271 subjects with mild to moderate COPD who participated in the
Lung Health Study (LHS). The subjects were followed for approximately 7.5 years during which time their vital status, FEV1
and smoking status were ascertained. Using multiple regression methods, we determined the relationship of telomere
length to cancer and total mortality in these subjects. We also measured telomere length in healthy ‘‘mid-life’’ volunteers
and patients with more severe COPD. The LHS subjects had significantly shorter telomeres than those of healthy ‘‘mid-life’’
volunteers (p,.001). Compared to individuals in the 4
th quartile of relative telomere length (i.e. longest telomere group), the
remaining participants had significantly higher risk of cancer mortality (Hazard ratio, HR, 1.48; p=0.0324) and total mortality
(HR, 1.29; p=0.0425). Smoking status did not make a significant difference in peripheral blood cells telomere length. In
conclusion, COPD patients have short leukocyte telomeres, which are in turn associated increased risk of total and cancer
mortality. Accelerated aging is of particular relevance to cancer mortality in COPD.
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Introduction
The pathogenesis of chronic obstructive pulmonary disease
(COPD) is obscure. What is well known is that COPD is rare
before 40 years of age even among heavy smokers and its
incidence increases exponentially with aging. Furthermore, COPD
frequently aggregates with other age-related co-morbidities such as
osteoporosis, cardiovascular disease and dementia [1,2]. Together,
these data suggest that COPD is likely related to the aging process
[3]. Telomeres are biomarkers of aging. Telomeres are DNA caps
located at the end of chromosomes [4], protecting DNA against
degradation and remodelling, and preventing gene-to-gene fusion
or other gene rearrangements that may lead to cancerous changes
[5,6,7]. Owing to the end-replication problem in mature somatic
cells, telomere repeats are lost with each replicative cycle, until a
critical length is reached at which point cells undergo apoptosis or
other disruptive events [8]. This entire process is accelerated by
the presence of reactive oxygen species (ROS) or inflammation
[9,10,11], leading to short telomeres. Telomere length may thus be
a robust indicator of human ‘‘biological age’’. Previous studies in
COPD suggest that telomeres of peripheral leukocytes are
significantly shorter in COPD than in healthy control subjects
[12,13,14]. However, the relationship of telomere length in
peripheral leukocytes to important health outcomes such as
mortality and cancer has not been explored in COPD. We
hypothesized that COPD patients with longer telomeres would
have a lower mortality rate than those with shorter telomeres and
that telomere length serves as a predictor of mortality among
COPD patients.
Methods
Subjects and Controls
Lung Health Study (LHS). The study used clinical data and
biological materials obtained in the Lung Health Study (LHS), a
clinical trial sponsored by the National Heart, Lung and Blood
Institute. Following receipt of written informed consent, The LHS
initially enrolled 5887 smokers, aged 35–60 years with mild to
moderate airflow limitation (defined as a ratio of forced expiratory
volume at one second (FEV1) to forced vital capacity (FVC)#0.70
and 55,FEV1,90% predicted) across 10 centers in North
America [15]. Individuals who had a history of cancer (except
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infarction (in the past two years), angina, heart failure, stroke (in
the past two years), renal failure, insulin-requiring diabetes
mellitus, cirrhosis or other serious liver diseases, pulmonary
embolism, disorders of the central nervous system, narrow-angle
glaucoma, or any other major diseases which could have
compromised follow-up were excluded [16].
During the first 5-years of follow up, the participants’ lung
function and smoking status were assessed yearly. Participants
were categorized as sustained quitters if they were validated non-
smokers at each annual visit. Participants who were smokers at
each annual visit were continuing smokers. Those whose smoking
behaviour varied were classified as intermittent quitters. At year 5,
4,803 participants provided blood samples (representing 89% of
eligible participants). The blood samples were separated into their
component parts and were stored in 270uC freezers until use. The
study participants were then followed passively until the end of
2001 for a median follow-up of 7.5 years from the date of
venipuncture to study closure. During follow-up, the participants’
vital status and hospitalizations were recorded. A mortality and
morbidity board reviewed all patient records including death
certificates, eyewitness accounts, necropsy records, summaries of
interviews with attending physicians and hospitalization records
and assigned a cause to the mortality for all decedents. These data
were supplemented by a National Death Index which provided the
date and cause of death for all US study participants [16].
Mortality end points were the grouped into: coronary heart
disease, cardiovascular disease (which also included coronary heart
disease), lung cancer, all cancers (which included lung cancer),
respiratory disease excluding lung cancer, others, and unknown.
Healthy Aging Study Cohort. To compare the telomere
lengths of COPD subjects in LHS to a control group without
COPD, we used telomere data from middle-aged subjects from the
Healthy Aging Study, who were between 40 and 50 years of age
and were randomly recruited without regard to health or disease
status (i.e. ‘‘negative’’ controls) [17].
Advair, Biomarkers in COPD (ABC) cohort. As a second
control group (i.e. ‘‘positive’’ controls), we measured telomere
length of peripheral leukocytes obtained from patients with
moderate to severe COPD, as defined spirometrically by FEV1/
FVC ratio less than 70% and FEV1 less than 80% of predicted,
who had at least 10 pack year smoking history and were at least 40
years of age [18]. The results of this study have been previously
published [13].
Leukocyte DNA Extraction
The concentration of DNA from peripheral blood collected at
year 5 was determined using a NanoDrop 8000 spectrophotom-
eter (Thermo Scientific, Wilmington, USA). The DNA samples
were diluted to 1 ng/mLi n1 6 Tris-EDTA buffer and stored at
220uC for subsequent use in quantitative polymerase chain
reaction (qPCR).
Measurement of Telomere Length
Peripheral blood leukocyte telomeres were measured using a
modified qPCR protocol described by Cawthon [19]. The primer
sequences (written 59R39) were: tel 1, GGTTTTTGAG -
GGTGAGGGTGAGGGTGAGGGTGAGGGT; tel 2, TCCC-
GACTATCCCTATCCCTATCCC -TATCCCTATCCCTA;
36B4u, CAGCAAGTGGGAAGGTGTAATCC; 36B4d, CCCA-
TTCTA -TCATCAACGGGTACAA. The reference single copy
gene used was 36B4 and the final concentrations of the primers
(Sigma, The Woodlands, TX) were tel 1, 270 nM; tel 2, 900 nM,
36B4u, 300 nM; 36B4d, 500 nM.
Telomere length measurement was performed in triplicate for
all the samples in a 384 well Clear Optical Reaction Plate (Applied
Biosystems, Foster City, CA). Reference DNA obtained from the
Coriell Institute (Camden, NJ) was assayed in triplicate on each
PCR plate to account for interplate measurement variation. Each
well contained 10 mL QuantiTect SYBR Green PCR Master Mix
(QIAGEN, Mississauga, ON) and a final DNA concentration of
0.25 ng/mL. After loading, plates were sealed with MicroAmp
Optical Adhesive Film (Applied Biosystems, Foster City, CA) and
centrifuged briefly at 2,500 rpm. The reactions were performed in
an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City CA). The thermal cycling profile for both
telomere and single copy gene amplification began with 50uC for
2 min then 95uC for 2 min. For the telomere PCR, there followed
30 cycles of 95uC for 15 s and 54uC for 2 min. The 36B4 cycling
profile was followed by 35 cycles of 95uC for 15 s and 58uC for
1 min. Telomere length was quantified as a relative T/S
(T=telomere, S=single copy gene) ratio, calculated according
to Cawthon’s formula [19].
Statistical Analysis
The telomere lengths of peripheral blood leukocytes were
standardized to the reference single copy gene (T/S). For analytic
purposes, the participants were divided into quartiles based on
their T/S ratio. The clinical characteristics were then compared
using a chi-square test for dichotomous variables (using appropri-
ate degrees of freedom) and Cochran-Armitage test for trend for
continuous variables. The primary endpoint for this study was all-
cause mortality. We compared the risk of all-cause mortality across
the quartiles over the follow-up period using a Kaplan-Meier (K-
M) Method for the univariate analysis and a Cox proportional
hazards model for the multivariate analysis. The K-M survival
curves across the T/S quartiles were compared using a log-rank
test. In the multivariate model, we included the following
covariates: age, gender, body mass index (BMI), smoking status
through the first 5 years of follow-up, pack-years of smoking, blood
pressure at year 5, and FEV1 at year 5. FEV1, BMI, blood pressure
measurements and pack-years of smoking did not significantly
affect the results of the model. Thus, they were dropped in the
final analysis. A similar approach was used for cause-specific
mortality endpoints. T/S ratios across the smoking groups were
compared using the Kruskal-Wallis test, as the data were non-
normally distributed. Correlations between the T/S ratio and
variables such as FEV1 at year 5 and age were tested using the
Spearman test for non-parametric variables. P-values less than
0.05 (using a two-tailed test) were considered significant. All
analyses were conducted using SAS (version 9.1, Carey, N.C.).
The use of LHS and ABC study samples was approved by the
Providence Health Care/UBC Research Ethics Board. The use of
samples from the Healthy Aging Study was approved by the joint
Clinical Research Ethics Board of UBC and the British Columbia
Cancer Agency.
Results
Clinical Characteristics of the Participants
We successfully purified 4,578 genomic samples from the LHS.
Samples (n=165) with concentrations lower than 1 ng/mL were
excluded from the analysis. Samples with a high coefficient of
variation (.5%) in relative T/S ratio and those that did not
amplify were also excluded, leaving 4,271 samples (93.3%) for the
final analysis (Figure 1). Table 1 shows the main clinical
characteristics of the LHS participants according to the relative
length of peripheral blood leukocyte telomeres.
Telomeres and COPD
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There were no significant differences in age, sex, BMI, race or
cumulative smoking exposure (pack-years) across the quartiles of
T/S ratio (Table 1). The median (relative) telomere length (T/S
ratio) was 0.3256 (interquartile range: 0.2124 to 0.5000). Telomere
length was non-normally distributed with no significant differences
between males (n=2685; median=0.3246; interquartile range,
0.2133–0.4987) and females (n=1586; median=0.3268; inter-
quartile range, 0.2102–0.5016). There was no significant relation-
ship between the T/S ratio and age (r=20.020; p=0.195),
FEV1% predicted (r=0.001; p=0.946) or BMI (r=0.011;
p=0.474).
Mortality Risk Prediction by Telomere Length
During a median follow-up of 7.51 years (interquartile range,
7.41 to 7.58 years) from blood collection to 2001, 399 of 4271
participants (9.34%) died; 202 from cancer (4.73%), 127 from lung
cancer (2.87%), 52 from cardiovascular disease (1.22%) and 27
from non-malignant respiratory causes (0.867%). The T/S ratio
was significantly related to all-cause mortality but the risk was non-
linear (Table 2). The risk of all-cause mortality was similar across
the first 3 quartiles (p.0.05) of T/S ratio but dropped significantly
in the 4
th quartile (hazard ratio, HR, 1.30; p=0.0331 comparing
1
st to 3
rd quartiles to 4
th quartile). Adjustment for covariates made
no significant differences to the overall results (adjusted HR, 1.29;
p=0.0425). These data were largely driven by cancer mortality
(Table 2). Compared to individuals in the 4
th quartile of T/S
ratio, the remaining participants had significantly higher risk of
cancer mortality (adjusted HR, 1.48 p=0.0324). The hazard ratio
of lung cancer mortality failed to reach significance and this may
be due to the relatively small number of lung cancer mortality
cases during follow-up (adjusted HR, 1.48; p=0.0886). The K-M
survival analyses of all-cause mortality and cancer mortality are
shown in figures 2 and 3, respectively.
Telomere Length and Smoking Status
Because cigarette smoke is suggested to accelerate telomere
attrition, we evaluated the effect of smoking status on leukocyte
Figure 1. The number of participants excluded from analyses
and reasons for exclusion. At year five, 5413 participants were alive
and were eligible for venipuncture. Of those, 4803 provided blood
samples (89% of eligible participants). DNA was extracted and purified
from the buffy coat samples from a total of 4578 participants. Samples
with concentration below 1 ng/uL were excluded and 4413 samples
were used for telomere length measurement. Samples with greater
than 5% coefficient of variation (CV) and with no amplification were
excluded. Data analyses were carried out using telomere length
measurements of 4271 subjects.
doi:10.1371/journal.pone.0035567.g001
Table 1. Clinical and demographic features of the LHS participants, by quartiles of leukocyte telomere length, in the LHS
(N=4271).
Characteristic Quartile P value for trend
12 3 4
Number of subjects 1068 1068 1068 1067
Age (years) 53.966.7 53.466.7 53.366.9 53.466.7 0.145
Gender (% male) 62.3 64 62.6 62.6 0.965
BMI 25.564.0 25.563.8 25.663.8 25.664.0 0.639
Race (% Caucasian) 96.7 96.9 95.5 96.0 0.157
Continuous smokers (%) 51.2 55.8 56.9 53.6 0.850
Intermittent smokers (%) 30.6 28.1 26.6 26.4
Sustained quitters (%) 18.2 16.1 16.5 20.0
Pack years 40.2618.0 40.2618.0 39.6618.4 39.7619.0 0.194
FEV1(% predicted) at baseline 78.468.8 78.768.7 78.369.9 78.4610.6 0.415
FEV1 (% predicted) after 5 years 75.2611.6 75.4611.9 74.4612.7 75.6612.6 0.486
Abbreviations: FEV1, forced expiratory volume in 1 second; BMI, body mass index. Study participants were divided into 4 identical groups based on the telomere length,
1
st quartile being the shortest and 4
th quartile being the longest. Data are presented as mean 6 SD and tested with Cochran-Armitage test for trend.
doi:10.1371/journal.pone.0035567.t001
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length between the quitter group and the smoker groups (sustained
quitters versus intermittent quitters: p=0.074; sustained quitters
versus continuous smokers: p=0.605).
We also compared telomere length of various smoker groups in
the LHS to the mid-life comparison group (mean age6SE:
45.3460.51). The telomere length of the mid-life controls was
significantly longer than all three smoker groups in the LHS
(sustained quitter: p,0.001; intermittent quitter: p,0.001;
continuous smoker: p,0.001) (Figure 4). The significant
difference persisted when controlled for age.
Because the mid-life control participants’ samples were collected
more recently compared to the LHS genomic samples, ABC study
samples were also compared to rule out telomere perturbation
related to long-term storage of blood samples. There was no
significant difference in leukocyte telomere length between LHS
and ABC subjects (p=0.4820), suggesting that storage condition is
not the main driver of the difference between mid life controls and
LHS samples shown in Figure 4.
Discussion
The most important and novel finding from our study was that
the telomere length of peripheral blood leukocytes of patients with
COPD was significantly related to the risk of all-cause and cancer
mortality over a median follow up of 7.5 years, independent of
possible confounders such as chronological age, smoking status
and lung function. Interestingly, the relationship was non-linear
with the lowest risk observed in the group with the longest T/S
ratio, suggesting a threshold effect. We also found that although
smoking status was not associated with differential telomere
lengths, the telomere length of peripheral leukocytes from LHS
participants, who all had significant smoking history (on average
more than 40 pack-years) at the time of blood collection, was
significantly shorter (by more than 50%) than that of healthy
subjects of similar age. Together, these data suggest that prior
Figure 2. Kaplan-Meier survival curves for all-cause mortality by leukocyte telomere length of 4271 subjects in the LHS. Subjects are
divided into quartiles 1, 2, and 3 (shorter telomeres) versus quartile 4 (longest telomeres). P value was derived from multivariable Cox models. Hazard
ratio between Q1–3 and Q4 is 1.48 (95% CI, 1.02–1.66).
doi:10.1371/journal.pone.0035567.g002
Table 2. Hazard ratio of total and disease specific causes of mortality according to telomere length.
End Point 1
st vs 4
th quartile 2
nd vs 4
th quartile 3
rd vs 4
th quartile 1–3 versus 4
th quartile
Total Mortality 1.20 (0.90, 1.61) 1.18 (0.88, 1.59) 1.48 (1.12, 1.96) 1.29 (1.01, 1.64)
Cancer Mortality 1.43 (0.94, 2.16) 1.35 (0.88, 2.07) 1.65 (1.10, 2.49) 1.48 (1.04, 2.11)
Lung Cancer Mortality 1.40 (0.83, 2.38) 1.53 (0.91, 2.60) 1.51 (0.89, 2.56) 1.48 (0.94, 2.33)
CVD Mortality 2.09 (0.85, 5.12) 1.95 (0.79, 4.84) 2.19 (0.90, 5.33) 2.08 (0.94, 4.61)
Respiratory Mortality 1.69 (0.57, 5.06) 1.59 (0.52, 4.86) 3.02 (1.10, 8.32) 2.09 (0.81, 5.36)
Adjustments were made for age, sex, smoking status (i.e. sustained smokers, intermittent quitters, quitters). Inclusion of other variables such as FEV1% predicted, body
mass index and pack years of smoking made no significant differences to the results.
doi:10.1371/journal.pone.0035567.t002
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leading to short telomeres and, in its extreme, short telomeres
are associated with increased risk of cancer and total mortality in
COPD patients.
The mechanism that underlies the association between short
telomeres in leukocytes and mortality in COPD patients is
unknown. The first possibility is that oxidative stress from
environmental oxidants (cigarette smoke) and chronic inflamma-
Figure 4. Telomere length in smoker groups in LHS and mid-life controls. Mid-life controls (n=53; mean age=45.34), sustained quitters
(n=753; mean age=54.07), intermittent quitters (n=1,192; mean age=53.26), continuous smokers (n=2,319), COPD (ABC) controls (n=20; mean
age=64.80). Results are expressed as mean 6 standard error. *p,0.001 vs. mid-life control group.
doi:10.1371/journal.pone.0035567.g004
Figure 3. Kaplan-Meier survival curves for cancer mortality by leukocyte telomere length of 4271 subjects in the LHS. Subjects are
divided into quartiles 1, 2, and 3 (shorter telomeres) versus quartile 4 (longest telomeres). P value was derived from multivariable Cox models. HR
between Q1–3 and Q4 is 1.48 (95% CI, 1.04–2.11).
doi:10.1371/journal.pone.0035567.g003
Telomeres and COPD
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COPD patients to adverse outcomes including death from cancer.
However it is also possible that COPD patients who had an
adverse health outcome were genetically predisposed to acceler-
ated telomere shortening. The above explanations are not
mutually exclusive, as shorter telomeres in leukocytes of COPD
patients that develop cancer might reflect both constitutionally
short telomeres and further shortening by oxidative damage.
One of the strengths of this study was its longitudinal design.
The cohort was made up of mild to moderate COPD patients,
who were passively followed for a significant amount of time,
providing a unique opportunity to examine the relationship of
telomere lengths to clinical outcomes in COPD patients. Another
strength of this study was the large sample size. Previous clinical
studies examining the relationship between telomere length and
incidence of COPD have demonstrated mixed results owing
largely to small sample sizes [14,20].
There were also some limitations to the present study. First,
although the qPCR method of quantifying telomere length is well
accepted and widely used (for high throughput analysis), its signal
to noise ratio is still relatively low [21], which may have led to an
underestimation of the relationship between T/S ratio and adverse
outcomes in our study. Nevertheless, it was reassuring that the
qPCR methods produced similar results to those produced by flow
FISH (data not shown; available from authors upon request).
Second, most of the patients in this study had mild to moderate
disease; thus, the relationship of T/S ratio to health outcomes
across the full range of COPD severity is unknown. This may also
explain the lack of significant association between T/S ratio and
lung function in our study. Furthermore, all of the LHS
participants had heavy smoking exposure history before blood
samples were collected (on average more than 40 pack-years of
smoking), which may have obfuscated the relationship between
smoking cessation (status) and T/S ratio in our study. Third, the
LHS did not have biological materials from lungs. Thus, the
relationship of T/S ratio in peripheral blood leukocytes to that in
lung tissues is uncertain. Lastly, telomere length was measured
using genomic samples taken from buffy coat which also contains
terminally differentiated cells and we did not have serial
measurements from the same subjects before and after smoking
cessation. Thus, it is uncertain whether telomeres in peripheral
blood cells can ‘‘recover’’ following smoking cessation or whether
it is an irreversible, progressive process.
Interestingly, we did not find a significant relationship between
chronological age and T/S ratio. While the exact reason for this
unclear, this finding is consistent with previous studies, which have
shown that the relationship between chronological age and T/S
ratio is significantly mitigated by cigarette smoking and by the
presence of COPD. In Savale et al. [14], for instance, in the
control population, there was a strong relationship between
chronological age and T/S ratio (p=.0003). However, in patients
with COPD, this relationship was significantly weakened
(p=0.42). Smoking also reduces T/S ratio [22,23] and attenuates
the relationship between chronological age and T/S ratio [22,23].
In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study, which similar to our study in that it evaluated
only smokers, there was no significant relationship between
chronological age and T/S ratio [22].
In summary, we have shown that COPD patients who have
reduced telomere lengths in their peripheral blood leukocytes are
at higher risk of total and cancer-related mortality. Our results are
consistent with previous studies demonstrating a link between
reduced telomeres and increased risk of cancer mortality in non-
COPD elderly populations [24]. COPD is a worldwide epidemic
and is projected to increase as smoking frequencies rise and the
population ages [25]. Our results indicate that some COPD
patients have short telomeres. This may be a distinct phenotype
that is associated with increased risk of cancer and total mortality.
Since telomeres can be readily measured in the peripheral
circulation, telomeres are a promising biomarker in identifying
this phenotype. However, given the variation in the T/S data,
additional studies will be needed to address the impact of this
measurement on clinical outcomes of COPD.
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